Document:

EXHIBIT 1029

		
			Exhibit 10.29
		

		
			EMPLOYMENT AGREEMENT
		

		
			AGREEMENT (this “Agreement”) made as of April 20, 2015 (the “Effective Date”), by and between Fairway Group Holdings Corp., a Delaware corporation with an office at 2284 12th Avenue, New York, New York 10027 (the “Company”), and Maureen Minard (the “Executive”).
		

		
			WITNESSETH:
		

		
			WHEREAS, the Company and its subsidiaries (collectively, the “Fairway Group”) desire that Executive be employed to serve in an executive capacity with the Fairway Group, and Executive desires to be so employed by the Fairway Group, upon the terms and subject to the conditions set forth herein.
		

		
			NOW, THEREFORE, in consideration of the premises and of the mutual promises, representations and covenants herein contained, the parties hereto agree as follows:
		

		
			1. EMPLOYMENT.
		

		
			The Company hereby employs Executive and Executive hereby accepts such employment, subject to the terms and conditions herein set forth.  Executive shall hold the office of Senior Vice President—Chief Information Officer of the Company reporting to the Chief Executive Officer of the Company or such other senior executive officer of the Company as the Chief Executive Officer shall specify (the Chief Executive Officer or such other senior executive officer the “Supervisory Officer”).
		

		
			2. TERM.
		

		
			The term of employment under this Agreement began on the Effective Date and shall continue until April 30, 2017, subject to prior termination in accordance with the terms hereof (the “Initial Term”).  The Initial Term shall be automatically extended for successive additional periods of one (1) year (each such one-year period, an “Additional Term”), unless either party shall have given written notice to the other party of non-extension at least sixty (60) days prior to the end of the Initial Term or the then applicable Additional Term (any period during which Executive is employed hereunder the “Employment Term”).
		

		
			3. COMPENSATION.
		

		
			(a)As compensation for the employment services to be rendered by Executive hereunder, including all services as an officer or director of any member of the Fairway Group, the Company agrees to pay, or cause to be paid, to Executive, and Executive agrees to accept, payable in equal installments in accordance with Company payroll practices then in existence, an initial annual salary of $275,000 (the “Annual Salary”).  Executive’s Annual Salary for any year following 2015 shall be determined by the Board of Directors of the Company (the “Board”) in its sole discretion, but shall not in any year be reduced below the rate for the previous year.
		

		
			(b)During each fiscal year of the Employment Term, Executive shall be eligible for an annual performance bonus, if any, as may be determined by the Board from time to time in its sole discretion.  Such bonus will be targeted at thirty-five percent (35%) of Executive’s Annual Salary (prorated to the extent Executive is not employed during the entire fiscal year (based on the number of days during such fiscal year that Executive was employed)) and will be based upon, among other things, the Executive’s performance and the Company’s financial performance.  
		

		
			4. EXPENSES.
		

		
			The  Company shall pay or reimburse Executive, upon presentment of suitable vouchers, for all reasonable business expenses which may be incurred or paid by Executive in connection with her employment 
		

		

		

		 

 

		
		

		
			hereunder in accordance with Company policy as established from time to time by the Board.  Executive shall comply with such restrictions and shall keep such records as the Company may reasonably deem necessary to meet the requirements of the Internal Revenue Code of 1986, as amended from time to time (the “Code”), and regulations promulgated thereunder.
		

		
			5. OTHER BENEFITS.
		

		
			Executive shall be entitled to four (4) weeks paid vacation for each full calendar year, beginning with calendar year 2015 (the timing of vacations to be subject to the reasonable approval of the Chief Executive Officer), and to participate in such benefit plans and arrangements and receive other benefits on terms consistent with other officers of the Company at the same level as Executive (including short- and long-term disability insurance, 401(k) plan, hospital, major medical insurance, dental and group life insurance plans in accordance with the terms of such plans), all as determined from time to time by the Board (the “Benefit Plans”).  During the Employment Term, the Company shall provide a car allowance of $250 per week payable in equal installments at the same time Executive receives her salary.  Executive shall not be entitled to rollover or otherwise accumulate unused vacation days from year-to-year without the prior consent of the Chief Executive Officer.  
		

		
			6. DUTIES.
		

		
			(a)Executive shall have such authority and responsibilities and shall perform such reasonable duties and functions as are typically performed by executives in her position and such other reasonable duties and functions commensurate with her position as the Supervisory Officer and Board lawfully assign to her.  Executive shall comply in the performance of her duties with the policies of the Fairway Group and the Board, and be subject to the direction of the Supervisory Officer and the Board.
		

		
			(b)During the Employment Term, Executive shall devote all of her business time and attention, reasonable vacation time and absences for sickness excepted, to the business of the Fairway Group, as necessary to fulfill her duties; provided,  however, that Executive may engage in other activities so long as such activities do not unreasonably interfere with Executive’s performance of her duties hereunder and do not violate Section 9 hereof.  Executive shall perform the duties assigned to her in compliance in all material respects with the Company’s Code of Conduct.
		

		
			(c)Nothing contained in this Section 6 or elsewhere in this Agreement shall be construed to prevent Executive from investing or trading in non-competing investments as she sees fit for her own account, including real estate, stocks, bonds, securities, commodities or other forms of investments.
		

		
			7. TERMINATION OF EMPLOYMENT; EFFECT OF TERMINATION.
		

		
			(a)Executive’s employment hereunder shall terminate upon the first to occur of the following:
		

		
			(i)upon thirty (30) days’ prior written notice to Executive upon the determination by the Board that Executive’s employment shall be terminated for any reason which would not constitute “justifiable cause”;
		

		
			(ii)upon written notice to Executive from the Board of termination for “justifiable cause”;
		

		
			(iii) automatically and without notice upon the death of Executive;
		

		
			(iv)in accordance with the terms of subsection (e) hereof upon the “disability” (as defined below) of Executive; 
		

		

		

		 

		

			1

		

 

		
		

		
			(v)upon thirty (30) days’ prior written notice by Executive to the Company of Executive’s voluntary termination of employment without “good reason”; or
		

		
			(vi) upon written notice by Executive to the Company of Executive’s termination of employment for “good reason” in accordance with Section 7(b)(ii).
		

		
			Upon the Company giving notice of termination pursuant to Section 7(a)(i) or (ii), or Executive giving notice of termination pursuant to Section 7(a)(v) or (vi), the Company may require that Executive immediately leave the Company’s premises, upon being given a reasonable opportunity to collect her personal effects and belongings, but such requirement shall not affect the effective date of termination of employment.
		

		
			(b)For the purposes of this Agreement:
		

		
			(i)The term “disability” shall mean the inability of Executive, due to illness, accident or any other physical or mental incapacity, to have performed the essential functions of her duties, with or without reasonable accommodation, for a period of four (4) months (whether or not consecutive) in any twelve (12) month period during the Employment Term, as reasonably determined by the Board.
		

		
			(ii)The term “good reason” shall mean: (A) a material diminution in Executive’s level of authority, duties, responsibilities or reporting lines; (B) a material reduction in Executive’s Annual Salary or target bonus; (C) a material change to the location at which Executive must perform the duties and obligations of her employment that is more than seventy five (75) miles from the Company’s New York City office; or (D) the Company’s material breach of this Agreement.  Notwithstanding the foregoing, “good reason” shall not be deemed to exist unless, no later than ninety (90) days following the date of the “good reason” event, Executive shall have given written notice to the Company specifying in reasonable detail the Company’s acts or omissions Executive alleges would constitute “good reason” and the Company fails to rescind any such act or cure any such omission within thirty (30) days following the receipt of such notice.  If such circumstances are not fully corrected in all material respects by the Company during the thirty (30) day cure period, Executive’s employment shall terminate for “good reason” upon the expiration of the cure period.
		

		
			(iii)The term “justifiable cause” shall mean: (A) Executive’s repeated failure to attempt in good faith (other than temporarily while physically or mentally incapacitated) or refusal to attempt to perform her duties pursuant to this Agreement after her receipt of written notice from the Chief Executive Officer of such failure or refusal specifying the details of the failure or refusal, if within ten (10) days of such notice, Executive fails to cure such failure or refusal; (B) Executive’s material breach of this Agreement, which breach is not cured by Executive within ten (10) days following her receipt of written notice specifying the details of such material breach; (C) Executive’s criminal act involving money or property of the Fairway Group or Executive’s breach (other than a de minimus breach) of her fiduciary duty; (D) Executive’s intentional and knowing material misrepresentation of the Company’s financial performance, operating results or financial condition to the Board; (E) any intentional unauthorized disclosure by Executive to any person, firm or corporation other than the members of the Fairway Group and their respective directors, managers, officers and employees, of any material confidential information or trade secret of the Fairway Group other than in the good faith performance of her duties; (F) Executive’s indictment or conviction of, or pleading guilty or nolo contendere to, a felony or a crime involving dishonesty, fraud or moral turpitude; (G) Executive’s willful misconduct materially damaging to the property, business or reputation of the Fairway Group (including any fraudulent act); (H) Executive’s unlawful use of controlled substances that, in the good faith judgment of the Chief Executive Officer, impairs Executive’s ability to effectively perform her duties hereunder or while on the Company’s premises; (I) any act or omission by Executive involving gross negligence in the performance of Executive’s duties that is materially adverse to the Fairway Group; or (J) Executive’s failure to materially comply with the Fairway Group’s policies, including without limitation, the Code of Conduct.
		

		

		

		 

		

			2

		

 

		
		

		
			(c)Upon any termination of Executive’s employment by the Company for “justifiable cause”, or voluntarily by Executive without “good reason” (including Executive electing not to extend the Employment Term), Executive shall not be entitled to any amounts or benefits hereunder other than such portion of Executive’s Annual Salary as has been accrued through the date of her termination of employment, reimbursement of expenses pursuant to Section 4 hereof and other amounts or benefits required by law or pursuant to the terms of the Benefit Plans.
		

		
			(d)If Executive should die during the Employment Term, this Agreement shall terminate immediately.  In such event, the estate of Executive shall thereupon be entitled to receive (i) such portion of Executive’s Annual Salary as has been accrued through the date of her death, (ii) any accrued annual bonus for a prior fiscal year which remains unpaid as of the date of death and a pro rata portion of any bonus that Executive would have been entitled to receive pursuant to Section 3(b) in the fiscal year in which Executive died (based on the number of days Executive was alive during such fiscal year), payable when and if such bonus would otherwise have been payable had Executive’s employment not been terminated by reason of Executive’s death and (iii) reimbursement of expenses pursuant to Section 4.  Executive’s estate also shall be entitled to any amounts or benefits required by law or payable under the terms of the Benefit Plans.
		

		
			(e)Upon Executive’s disability in accordance with Section 7(b) hereof, the Company shall have the right to terminate Executive’s employment while she remains so disabled.  Any termination pursuant to this subsection (e) shall be effective on the date thirty (30) days after which Executive shall have received written notice of the Company’s election to terminate.  In such event, Executive shall thereupon be entitled to receive (i) such portion of Executive’s Annual Salary as has been accrued through the date of the termination of employment, (ii) any accrued annual bonus for a prior fiscal year which remains unpaid as of the date of termination and a pro rata portion of any bonus that Executive would have been entitled to receive pursuant to Section 3(b) in the fiscal year in which Executive became disabled (based on the number of days during such fiscal year that this Agreement was in effect), payable when and if such bonus would otherwise have been payable had Executive’s employment not been terminated by reason of Executive’s disability and (iii) reimbursement of expenses pursuant to Section 4.  Executive shall also be entitled to any amounts or benefits required by law or payable under the terms of the Benefit Plans.
		

		
			(f)Notwithstanding any provision to the contrary contained herein, in the event that Executive’s employment is terminated during the Employment Term by the Company without “justifiable cause” (other than due to death or disability), by Executive for “good reason” or by the Company electing not to extend the Employment Term, the Company shall, as of the end of the Employment Term, (i) continue to pay Executive her then current Annual Salary (subject to applicable tax withholding), payable in equal installments in accordance with the Company’s payroll practices then in existence, for a period of one (1) year from the date of termination and (ii) pay Executive’s COBRA continuation health coverage premiums (less the normal weekly contribution rate being paid by Executive at the time of termination, the payment of which shall be Executive’s responsibility) during the Severance Period, which amounts in (i) and (ii) above shall be in lieu of any and all other payments due and owing to Executive under the terms of this Agreement (other than any payments constituting reimbursement of expenses pursuant to Section  4 hereof, any payments or benefits required by law or payable under the terms of the Benefit Plans and the accrued annual bonus for a prior fiscal year and pro rata portion of the bonus, if any, referred to in the penultimate paragraph of this Section 7(f)).
		

		
			The period during which payments are made pursuant to clause (i) of this Section 7(f) is hereinafter referred to as the “Severance Period.”  The payments made pursuant to this Section 7(f) are collectively hereinafter referred to as the “Severance Payments.”  The Company’s obligation to make the Severance Payments shall be conditional upon (A) Executive executing and delivering to the Company within sixty (60) days after the date of her termination of employment a release (that is no longer subject to revocation under applicable law) in substantially the form of Exhibit A hereto, and (B) Executive’s compliance in all material respects with her obligations under Sections 9, 10, 11 and 12 hereof.  Notwithstanding anything to the contrary contained herein, the first Severance Payment shall be made on the sixtieth (60th) day following Executive’s “separation from service” (as defined in Section 409A of the Code) and shall include payment of all amounts that otherwise would be due prior thereto.
		

		

		

		 

		

			3

		

 

		
		

		
			In the event the Executive is entitled to receive Severance Payments pursuant to this Section 7(f), Executive shall also be entitled to the accrued annual bonus for a prior fiscal year which remains unpaid as of the date of termination and a pro rata portion (based on the number of days during such fiscal year that this Executive was employed) of any bonus Executive would have been entitled to receive pursuant to Section 3(b) in the fiscal year in which Executive’s employment was terminated, payable when and if such bonus would otherwise have been payable had Executive’s employment not been terminated.
		

		
			If the Company cannot provide the COBRA payments pursuant to this Section 7(f) without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act) or without subjecting the Executive to taxation on group health benefits, the Company will, in lieu thereof, provide to the Executive during the remainder of the Severance Period, a taxable monthly payment in an amount equal to the estimated cost of providing such benefits, calculated in good faith as of the time of commencement of such payments.
		

		
			(g)Upon any termination of Executive’s employment hereunder, Executive shall be entitled to: (i) receive such portion of Executive’s Annual Salary as has been accrued to date; (ii) reimbursement of expenses pursuant to Section 4 hereof; (iii) any payments or benefits required by law or payable under the terms of the Benefit Plans; (iv) treatment of any outstanding equity awards in conformance with the applicable equity plan(s) and/or award agreement(s); and (v) continued indemnification and coverage under directors and officers liability insurance, in each case, pursuant to Section 13 hereof.  Any termination of employment hereunder shall include termination from all applicable board and officer positions with any member of the Fairway Group.
		

		
			8. REPRESENTATIONS AND AGREEMENTS OF EXECUTIVE.
		

		
			(a)Executive represents and warrants that she is free to enter into this Agreement and to perform the duties required hereunder, and that there are no employment contracts or understandings, restrictive covenants or other restrictions, whether written or oral, preventing the performance of her duties hereunder.
		

		
			(b)Executive agrees to submit to a medical examination and to cooperate and supply such other information and documents as may be reasonably required by any insurance company in connection with the Company’s obtaining life insurance on the life of Executive, and any other type of insurance or fringe benefit as the Company shall determine from time to time to obtain.
		

		
			9. NON-COMPETITION.
		

		
			(a) In view of the unique and valuable services expected to be rendered by Executive to the Fairway Group, Executive’s knowledge of the trade secrets and other proprietary information relating to the business of the Fairway Group and in consideration of the compensation to be received hereunder, and Executive’s ownership interest in the Company, Executive agrees that during the period of her employment by the Company and for one year following her employment with the Company (the “Non-Competition Period”), Executive shall not, whether for compensation or without compensation, directly or indirectly, as an owner, principal, partner, member, shareholder, independent contractor, consultant, joint venturer, investor, licensor, lender or in any other capacity whatsoever, alone, or in association with any other person, carry on, be engaged or take part in, or render services (other than services which are generally offered to third parties) or provide advice to, own, share in the earnings of, invest in the stocks, bonds or other securities of, or otherwise become financially interested in, any entity primarily engaged in the retail grocery business that has a store, or is actively considering locating a store, within a 50-mile radius of (i) any existing store operated by the Fairway Group or (ii) any location where the Fairway Group is actively considering locating a store.  The record or beneficial ownership by Executive of up to one percent (1%) of the shares of any corporation whose shares are publicly traded on a national securities exchange or in the over-the-counter market shall not of itself constitute a breach hereunder.  In addition, Executive shall not, directly or indirectly, during the Non-Competition Period, except in the 
		

		

		

		 

		

			4

		

 

		
		

		
			good faith performance of her duties for the Fairway Group, request or cause any suppliers or customers with whom the Fairway Group has a business relationship to cancel or terminate any such business relationship with any member of the Fairway Group or solicit, interfere with, entice from or hire from any member of the Fairway Group any employee of any member of the Fairway Group.  Notwithstanding the foregoing, the provisions of this Section 9 shall not be violated by (x) general advertising or solicitation not specifically targeted at Fairway Group related persons or entities or (y) Executive’s serving as a reference upon request.  If the Company breaches its obligation to make the Severance Payments (other than in the circumstances described in the next sentence) or to comply with its obligations under Section 4 hereof, and such breach is not cured within thirty (30) days after written notice of such breach is provided to the Company by Executive, then in addition to any other remedies available to the Executive, Executive shall be released from her obligations under this Section 9.  If Executive does not comply in all material respects with her obligations under this Section 9 (other than in the circumstances described in the immediately preceding sentence), then notwithstanding anything herein to the contrary, the Company shall not be obligated to pay Executive any remaining portion of the Severance Payments.
		

		
			(b)During the Non-Competition Period:
		

		
			(i)Executive shall not make any oral or written statements, either directly or through other persons or entities, which are disparaging to any member of the Fairway Group or any of its affiliates, management, officers, directors, services, products, operations or other matters relating to the Fairway Group’s businesses; and
		

		
			(ii)The Fairway Group, formally or through its officers and directors, shall not make any oral or written statements, either directly or through other persons or entities, which are disparaging to Executive.
		

		
			Notwithstanding the foregoing provisions of this Section 9(b), it shall not be a violation of this Section 9(b) for Executive or the Fairway Group to (i) make truthful statements when required by order of a court or other body having jurisdiction, any governmental investigation or inquiry by a governmental entity, subpoena, court order, compulsory legal process, or as otherwise may be required by law, (ii) make traditional competitive statements in the course of promoting a competing business (except in violation of Section 9, 10 or 11 hereof), (iii) disclose that Executive is no longer employed by the Company, (iv) rebut inaccurate statements made by the other party or (v) for either party to make truthful statements to enforce her or its rights under this Agreement.
		

		
			(c)If any portion of the restrictions set forth in this Section 9 should, for any reason whatsoever, be declared invalid by a court of competent jurisdiction, the validity or enforceability of the remainder of such restrictions shall not thereby be adversely affected.
		

		
			(d)Executive acknowledges that the provisions of this Section 9 were a material inducement to the Company to enter into this Agreement and to employ Executive.  Executive further acknowledges that the territorial and time limitations set forth in this Section 9 are reasonable and properly required for the adequate protection of the business of the Fairway Group.  Executive hereby waives, to the extent permitted by law, any and all right to contest the validity of this Section 9 on the ground of breadth of its geographic or product and service coverage or length of term.  In the event any such territorial or time limitation is deemed to be unreasonable by a court of competent jurisdiction, Executive agrees to the reduction of the territorial or time limitation to the area or period which such court shall deem reasonable.
		

		
			(e)The existence of any claim or cause of action by Executive against the Company or any other member of the Fairway Group shall not constitute a defense to the enforcement by the Fairway Group of the foregoing restrictive covenants, but such claim or cause of action shall be litigated separately.
		

		

		

		 

		

			5

		

 

		
		

		
			10.INVENTIONS AND DISCOVERIES.
		

		
			(a) Executive shall promptly and fully disclose to the Fairway Group, with all necessary detail for a complete understanding of the same, all developments, know-how, discoveries, inventions, improvements, concepts, ideas, writings, formulae, processes and methods (whether copyrightable, patentable or otherwise) made, received, conceived, developed, acquired or written during working hours, or otherwise, by Executive (whether or not at the request or upon the suggestion of the Fairway Group) during the Employment Term, solely or jointly with others, using the Fairway Group’s resources, or relating to any current or proposed business or activities of the Fairway Group known to her as a consequence of her employment or the rendering of services hereunder (collectively, the “Subject Matter”).
		

		
			(b)Executive hereby assigns and transfers, and agrees to assign and transfer, to the Fairway Group all her rights, title and interest in and to the Subject Matter, and Executive further agrees to deliver to the Fairway Group any and all drawings, notes, specifications and data relating to the Subject Matter, and to execute, acknowledge and deliver all such further papers, including applications for trademarks, copyrights or patents, as may be necessary to obtain trademarks, copyrights and patents for any thereof in any and all countries and to vest title thereto in the Fairway Group.  Executive shall assist the Fairway Group in obtaining such trademarks, copyrights or patents during the term of this Agreement, and any time thereafter on reasonable notice and at mutually convenient times, and Executive agrees to testify in any prosecution or litigation involving any of the Subject Matter; provided,  however, that following termination of employment Executive shall be reasonably compensated for her time and reimbursed her reasonable out-of-pocket expenses incurred in rendering such assistance or giving or preparing to give such testimony if it is required after the Non-Competition Period.
		

		
			11.NON-DISCLOSURE OF CONFIDENTIAL INFORMATION.
		

		
			(a)Executive shall not, during the term of this Agreement, or at any time following expiration or termination of this Agreement, directly or indirectly, disclose or permit to be known, other than in the good faith performance of her duties (including without limitation disclosures to the Fairway Group’s advisors and consultants) or as is required by law (in which case Executive shall give the Company prior written notice of such required disclosure) or with the prior written consent of the Chief Executive Officer, to any person, firm or corporation, any confidential information acquired by her during the course of, or as an incident to, her employment hereunder, relating to the Fairway Group, any client, vendor or customer of the Fairway Group, or any corporation, partnership or other entity owned or controlled, directly or indirectly, by any of the foregoing, or in which any of the foregoing has a beneficial interest, including, but not limited to, the business affairs of each of the foregoing.  Such confidential information shall include, but shall not be limited to, proprietary technology, trade secrets, patented processes, research and development data, know-how, market studies and forecasts, competitive analyses, pricing policies, employee lists, personnel policies, the substance of agreements with customers, suppliers, landlords and others, marketing or dealership arrangements, servicing and training programs and arrangements, customer lists and any other documents embodying such confidential information.  This confidentiality obligation shall not apply to any confidential information which becomes publicly available from sources unrelated to the Fairway Group.
		

		
			(b)All information and documents relating to the Fairway Group as hereinabove described (or other business affairs) shall be the exclusive property of the Fairway Group, and Executive shall use commercially reasonable business efforts to prevent any publication or disclosure of any such information or documents in her possession or control.  Upon termination of Executive’s employment with the Company, all documents, records, reports, writings and other similar documents containing confidential information, including copies thereof, then in Executive’s possession or control shall be returned and left with the Company.  The foregoing obligations shall not extend to Executive’s rolodex, address books, or other documents to the extent such rolodex, address books or other documents contain only contact information.
		

		

		

		 

		

			6

		

 

		
		

		
			12.SPECIFIC PERFORMANCE.
		

		
			Executive agrees that if she breaches, or threatens to commit a breach of, any of the provisions of Sections 9, 10 or 11 (the “Restrictive Covenants”), the Fairway Group shall have, in addition to, and not in lieu of, any other rights and remedies available to the Fairway Group under law and in equity, the right to injunctive relief and/or to have the Restrictive Covenants specifically enforced by a court of competent jurisdiction, without the posting of any bond or other security, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Fairway Group and that money damages would not provide an adequate remedy to the Company.  Notwithstanding the foregoing, nothing herein shall constitute a waiver by Executive of her right to contest whether a breach or threatened breach of any Restrictive Covenant has occurred.
		

		
			13.INDEMNIFICATION; D&O INSURANCE.
		

		
			(a)The Company shall indemnify Executive and hold her harmless as and to the extent provided in that certain Indemnification Agreement, dated as of April 20, 2015, by and between the Company and Executive.  This obligation shall survive the termination of Executive’s employment.
		

		
			(b)The Company shall cover Executive under directors and officers liability insurance both during and, while liability exists, after the Employment Term in the same amount and to the same extent as the Company covers its other officers and directors.
		

		
			14.AMENDMENT OR ALTERATION.
		

		
			No amendment or alteration of the terms of this Agreement shall be valid unless made in writing and signed by both of the parties hereto.
		

		
			15.GOVERNING LAW.
		

		
			This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed therein.
		

		
			16.CHOICE OF FORUM; WAIVER OF JURY TRIAL.
		

		
			Executive and the Fairway Group agree that any dispute between Executive and the Fairway Group shall be resolved exclusively in the United States District Court for the Southern District of New York or the applicable state court located in New York County, New York and Executive consents to personal jurisdiction  in said courts.  EACH OF THE COMPANY AND EXECUTIVE HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY ACTION, PROCEEDING OR CLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
		

		
			17.SEVERABILITY.
		

		
			The holding of any provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall not affect any other provision of this Agreement, which shall remain in full force and effect.
		

		
			18.WITHHOLDING.
		

		
			The Company may deduct and withhold from the payments to be made to Executive hereunder any amounts required to be deducted and withheld by the Company under the provisions of any applicable statute, law, regulation or ordinance now or hereafter enacted.
		

		

		

		 

		

			7

		

 

		
		

		
			19.NOTICES.
		

		
			Any notices required or permitted to be given hereunder shall be sufficient if in writing, and if delivered by hand or courier, or sent by certified mail, return receipt requested, to the address set forth above in the case of the Company and Executive’s address as set forth in the Company’s records, or such other address as either party may from time to time designate in writing to the other, and shall be deemed given as of the date of the delivery or at the expiration of three days in the event of a mailing.
		

		
			20.COUNTERPARTS AND FACSIMILE SIGNATURES.
		

		
			This Agreement may be signed in counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this Agreement.  For purposes of this Agreement, a facsimile copy of a party’s signature shall be sufficient to bind such party.
		

		
			21.WAIVER OR BREACH.
		

		
			It is agreed that a waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed, as a waiver of any subsequent breach by that same party.
		

		
			22.ENTIRE AGREEMENT AND BINDING EFFECT.
		

		
			This Agreement contains the entire agreement of the parties with respect to the subject matter hereof, supersedes all prior and contemporaneous agreements, both written and oral, between the parties with respect to the subject matter hereof, and may be modified only by a written instrument signed by each of the parties hereto.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective legal representatives, heirs, distributors, successors and assigns; provided,  however, that (i) Executive shall not be entitled to assign or delegate any of her rights or obligations hereunder without the prior written consent of the Company and (ii) the Company shall only be permitted to assign this Agreement to an assignee of all or substantially all of the assets of the Company and if such assignee assumes the obligation hereunder in writing.  It is intended that Sections 9, 10, 11, 12 and 16 benefit each of the Company and each other member of the Fairway Group, each of which is entitled to enforce the provisions of Sections 9, 10, 11, 12 and 16.
		

		
			23.SURVIVAL.
		

		
			Except as otherwise expressly provided herein, the termination of Executive’s employment hereunder or the expiration of this Agreement shall not affect the enforceability of Sections 4, 7, 9, 10, 11, 12, 13, 16, 22, 23, 24 and 25 hereof.
		

		
			24.280G.
		

		
			Notwithstanding anything set forth herein to the contrary, if any payment or benefit Executive would receive from the Company pursuant to this Agreement or otherwise (“Payment”) would constitute a “parachute payment” within the meaning of Section 280G of the Code and, but for this Section 24, would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall equal the Revised Amount which may under clause (a) in the following sentence be a lesser amount than the full Payment.  The “Revised Amount” shall be either (a) or (b) whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the payment may be subject to the Excise Tax and where: (a) is the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax and (b) is the full, unreduced, total Payment.  If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment is reduced to the amount in clause (a) above, unless to the extent permitted by Code Section 280G and 409A Executive designates another order, the reduction shall occur in the 
		

		

		

		 

		

			8

		

 

		
		

		
			following order: (A) cash payments shall be reduced first and in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced; (B) accelerated vesting of equity awards shall be cancelled/reduced next and in the reverse order of the date of grant for such equity awards (i.e., the vesting of the most recently granted stock awards will be reduced first), with full-value awards reversed before any stock option or stock appreciation rights are reduced; and (C) employee benefits shall be reduced last and in reverse chronological order such that the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced.  Except as set forth in the next sentence, all determinations to be made under this Section 24 shall be made by the Company’s independent registered public accounting firm immediately prior to the event giving rise to the Payment (or if such firm cannot make such determination, an independent accounting firm selected by the Company (and reasonably acceptable to Executive)), which accounting firm shall provide its determinations and any supporting calculations and documentation to the Company and Executive promptly after the change in ownership or effective control of the Company or ownership of a substantial portion of the Company’s assets (within the meaning of Code Section 280G).  In making its determination, the accounting firm shall take into account (if applicable) the value of Executive’s non-competition covenant set forth in Section 9 of this Agreement.  The costs and expenses of the accounting firm and, if a valuation firm is required by the accounting firm to perform its calculations, such valuation firm shall be borne by the Company.
		

		
			25.409A COMPLIANCE.
		

		
			If Executive is a “specified employee” within the meaning of Treasury Regulation Section 1.409A-l(i) as of the date of the Executive’s separation from service, then Executive shall not be entitled to any Severance Payments or other benefits pursuant to Section 7 of this Agreement until the earlier of (a) the date which is six (6) months after the date of Executive’s separation from service or (ii) the date of Executive’s death.  This paragraph shall only apply if, and to the extent, required in order to comply with Section 409A of the Code.  Any amounts otherwise payable to Executive upon or in the six-month period following Executive’s separation from service that are not so paid by reason of this paragraph shall be paid to Executive (or Executive’s estate, as the case may be) as soon as practicable (and in all events within twenty (20) days) after the expiration of such six-month period or (if applicable, the date of Executive’s death), and any remaining payments due to the Executive under this Agreement shall be paid as otherwise provided herein.
		

		
			For the purposes of this Agreement, a “termination of employment” or words of like import shall mean a “separation from service” within the meaning of Section 409A of the Code and the regulations issued thereunder.  Any taxable reimbursements pursuant to Section 4 shall be paid to Executive on or before the last day of Executive’s taxable year following the taxable year in which the related expense was incurred.  Reimbursements pursuant to Section 4 are not subject to liquidation or exchange for another benefit and the amount of such benefits that Executive receives in one taxable year shall not affect the amount of such reimbursements or benefits that Executive may receive in any other taxable year.  Each of the payments that may be made under this Agreement following Executive’s termination of employment shall be deemed to be a separate payment for purposes of applying Section 409A.
		

		
			It is intended that any amounts payable under this Agreement and the Company’s and Executive’s exercise of any authority or discretion hereunder shall comply with, and avoid the imputation of any tax, penalty or interest under Section 409A of the Code.  This Agreement shall be construed and interpreted consistent with that intent.  Notwithstanding the foregoing, Executive shall bear the cost of any failure to comply with Section 409A of the Code, unless and except to the extent that such tax, penalty or interest is incurred by reason of the Company’s willful breach of the provisions of this Agreement.
		

		
			26.FURTHER ASSURANCES.
		

		
			The parties agree to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement.
		

		

		

		 

		

			9

		

 

		
		

		
			27.CONSTRUCTION OF AGREEMENT.
		

		
			No provision of this Agreement or any related document shall be construed against or interpreted to the disadvantage of any party hereto by any court or other governmental or judicial authority by reason of such party having or being deemed to have structured or drafted such provision.
		

		
			28.HEADINGS.
		

		
			The Section headings appearing in this Agreement are for the purposes of easy reference and shall not be considered a part of this Agreement or in any way modify, demand or affect its provisions.
		

		
			IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date and year first above written.
		

		
			FAIRWAY GROUP HOLDINGS CORP.
		

		
			 
		

		
			By:  /s/ John E. Murphy    
		

		
			Name: John E. Murphy
Title: Chief Executive Officer
		

		
			 
		

		
			 
		

		
			 
		

		
			/s/ Maureen Minard
Maureen Minard
		

		
			 
		

		
			 
		

		

		

		 

		

			10

		

 

		EXHIBIT A
		

		
			FORM OF RELEASE
		

		
			In exchange for the payments and benefits set forth in the Employment Agreement between Fairway Group Holdings Corp. (the “Company”) and me dated April 20, 2015 (the “Agreement”), and to be provided following the Effective Date (as defined below) of this Release and subject to the terms of the Agreement, and my execution (without revocation) and delivery of this Release:
		

		
			1. (a) On behalf of myself, my agents, assignees, attorneys, heirs, executors and administrators, I hereby release the Company and its predecessors, successors and assigns, their current and former parents, affiliates, subsidiaries, divisions and joint ventures (collectively, the “Fairway Group”), and all of their current and former officers, directors, employees, and agents, in their capacity as Fairway Group representatives (individually and collectively, “Releasees”) from any and all controversies, claims, demands, promises, actions, suits, grievances, proceedings, complaints, charges, liabilities, damages, debts, taxes, allowances, and remedies of any type, including but not limited to those arising out of my employment with the Fairway Group (individually and collectively, “Claims”) that I may have by reason of any matter, cause, act or omission.  This release applies to Claims that I know about and those I may not know about occurring at any time on or before the date of execution of this Release.
		

		
			(b) This Release includes a release of all rights and Claims under, as amended, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967, the Rehabilitation Act of 1973, the Civil Rights Acts of 1866 and 1991, the Americans with Disabilities Act of 1990, the Employee Retirement Income Security Act of 1974, the Equal Pay Act of 1963, the Family and Medical Leave Act of 1993, the Fair Labor Standards Act of 1938, the Older Workers Benefit Protection Act of 1990, the Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1989, the Sarbanes-Oxley Act of 2002, the New York State Human Rights Act, and the New York City Human Rights Act, as well as any other federal, state, or local statute, regulation, or common law regarding employment, employment discrimination, termination, retaliation, equal opportunity, or wage and hour.  I specifically understand that I am releasing Claims based on age, race, color, sex, sexual orientation or preference, marital status, religion, national origin, citizenship, veteran status, disability and other legally protected categories.
		

		
			(c) This Release also includes a release of any Claims for breach of contract, any tortious act or other civil wrong, attorneys’ fees, and all compensation and benefit claims including without limitation Claims concerning salary, bonus, and any award(s), grant(s), or purchase(s) under any equity and incentive compensation plan or program.
		

		
			(d) In addition, I am waiving my right to pursue any Claims against the Company and Releasees under any applicable dispute resolution procedure, including any arbitration policy.
		

		
			I acknowledge that this Release is intended to include, without limitation, all Claims known or unknown that I have or may have against the Company and Releasees through the Effective Date of this Release.  Notwithstanding anything herein, I expressly reserve and do not release pursuant to this Release (and the definition of “Claims” will not include) (i) my rights with respect to the enforcement of the right to receive the payments (including without limitation the Severance Payments (as such term is defined in the Agreement) and benefits specified in the Agreement, (iii) any rights or interest under any Benefit Plan (as such term is defined in the Agreement), (iii) any right to indemnification pursuant to the Company’s Certificate of Incorporation and By-Laws and any indemnification agreement as in effect on the date hereof or otherwise, or the protections of the Company’s directors and officers liability insurance, (iv) any right to purchase shares of the Company’s stock after the date hereof under any stock option or restricted stock agreement between me and the Company, or (v) my rights as a stockholder of the Company.
		

		

		

		 

		

			-  1  -

		

 

		
		

		
			2. I acknowledge that I have had at least 211 calendar days from the date of my termination of employment with the Company (the “Termination Date”) to consider the terms of this Release, that I have been advised to consult with an attorney regarding the terms of this Release prior to executing it, that I have consulted with my attorney, that I fully understand all of the terms and conditions of this Release, that I understand that nothing contained herein contains a waiver of claims arising after the date of execution of this Release, and I am entering into this Release knowingly, voluntarily and of my own free will.  I further understand that my failure to sign this Release and return such signed Release to the Company, 2284 12th Avenue, New York, New York 10027 (attention: General Counsel) by 5:00 pm on the 222 day after the Termination Date will render me ineligible for the payments and benefits described herein and in the Agreement.
		

		
			3. I understand that once I sign and return this Release to the Company, I have 7 calendar days to revoke it.  I may do so by delivering to the Company, 2284 12th Avenue, New York, New York 10027 (attention: General Counsel) written notice of my revocation within the 7-day revocation period (the “Revocation Period”).  This Release will become effective on the 8th day after I sign and return it to the Company (“Effective Date”) provided that I have not revoked it during the Revocation Period.
		

		
			YOU ARE HEREBY ADVISED BY THE COMPANY TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE.
		

		
			I HAVE READ THIS RELEASE AND UNDERSTAND ALL OF ITS TERMS. I SIGN AND ENTER THIS RELEASE KNOWINGLY AND VOLUNTARILY, WITH FULL KNOWLEDGE OF WHAT IT MEANS.
		

		
			 
		

		
			
		

			
					
						By:

					
					
						 

				
	
					
						 Date:

					
					
						 

				

		
			 
		

		
			1 Change to 45 days in the case of a group termination under the ADEA
		

		
			2 If 21 days changed to 45 days, change to 46th
		

		 

		

			-  2  -Exhibit 10.15

 

EXCLUSIVE
PATENT SUBLICENSE AGREEMENT

 

This
EXCLUSIVE PATENT SUBLICENSE AGREEMENT (this “Agreement”) is made as of April 24, 2015 (the “Effective
Date”) by and between Next Dimension Technologies, Inc., a corporation organized under the laws of California, having
its principal office at 1 West Mountain Street, #11, Pasadena, CA 91102 (“NDT”), and CDx, Inc., a corporation
organized under the laws of Delaware, having its principal office at 4225 Executive Square Suite 600, La Jolla, CA 92037 (“CDx”).
NDT and CDx are each referred to herein as such or, individually, as a “Party” or, collectively, as “Parties.”

 

BACKGROUND

 

A.Pursuant
to an Amended and Restated License Agreement between NDT and the California Institute of Technology (“University”)
dated April 11, 2014 (the “University License Agreement”), NDT obtained an exclusive license to certain patents
and a non-exclusive license to certain other patents, in each case relating to chemical sensing technology; and

 

B.The
Parties have entered into that certain Joint Development Agreement dated November 1, 2013, as amended (“Joint Development
Agreement”) pursuant to which CDx engaged NDT to develop certain chemical sensing technology; and

 

C.NDT
owns or has rights under certain patent rights relating to chemical sensing technology; and

 

D.CDx
desires to obtain an exclusive sublicense under such patent rights, and NDT desires to grant such a sublicense to CDx, all on
the terms and conditions herein.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements provided herein below and other consideration, the receipt
and sufficiency of which is hereby acknowledged, NDT and CDx hereby agree as follows:

 

ARTICLE
1

DEFINITIONS

 

As
used in this Agreement, the following capitalized terms shall have the meanings indicated:

 

1.1
“Accessory” means any product, device, article of manufacture, or composition of matter in the CDx Field of
Use that is not a Sublicensed Product and that (1) requires the use of a Sublicensed Product, or (2) is intended for primary use
in conjunction with a Sublicensed Product. For the avoidance of doubt, exclusions from the definition of “Accessory”
include, but are not limited to, data, software and the like.

 

1.2
“Affiliate” means with respect to either Party, any corporation, limited liability company or other legal entity
which directly or indirectly controls, is controlled by, or is under common control of the subject Party as of the Effective Date
of this Agreement. For the purpose of this Agreement, “control” shall mean the direct or indirect ownership of at
least fifty-one percent (51%) of the outstanding shares on a fully diluted basis or other voting rights of the subject entity
to elect directors, or if not meeting the preceding, any entity owned or controlled by or owning or controlling at the maximum
control or ownership right permitted in the country where such entity exists. In addition, a party’s status as an Affiliate
shall terminate if and when such control ceases to exist.

 

    	 

    	 

    

  

1.3
“CDx Field of Use” means the use of sensors and their associated hardware, software, or signal processing technology
to characterize cannabis or to detect or to quantify compounds in cannabis except for applications in law enforcement.

 

1.4
Deductible Expenses” means the following expenses incurred in connection with sales or licensing of Sublicensed Products
to the extent actually paid by CDx or an Affiliate in accordance with generally recognized principles of accounting: (a) sales,
use or turnover taxes; (b) excise, value added or other, taxes or custom duties; (c) transportation, freight, and handling charges,
and insurance on shipments to customers; (d) trade, cash or quantity discounts or rebates to the extent actually granted; (e)
agent fees or commissions paid to third parties; and (f) rebates, refunds, and credits for any rejected or returned Sublicensed
Products or because of retroactive price reductions, rebates or chargebacks.

 

1.5
“Technology” means proprietary information, know-how, procedures, methods, prototypes, or designs existing
as of the Effective Date that is requested from NDT by CDx and consented to by NDT.

 

1.6
“Law” means, individually and collectively, any and all laws, ordinances, orders, rules, rulings, directives
and regulations of any kind whatsoever of any governmental or regulatory authority within the applicable jurisdiction.

 

1.7
“Sublicensed Product” means any product, device, system, article of manufacture, composition of matter, or
process or service in the CDx Field of Use that is covered by, or is made by a process covered by, any valid claim of the NDT
Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights or that utilizes Technology in material part.

 

1.8
“NDT Core Patent Rights” means that subset of NDT Exclusive Licensed Patent Rights and NDT Nonexclusive Licensed
Patent Rights listed in Exhibit C attached hereto.

 

1.9
“NDT Exclusive Licensed Patent Rights” means NDT’s rights under: (a) all patents and patent applications
listed in Exhibit A attached hereto, (b) any patents issuing therefrom; and (c) any patents or patent applications claiming a
right of priority thereto (including reissues, reexaminations, renewals, extensions, divisionals, continuations, continued prosecution
applications, continuations-in-part and foreign counterparts of any of the foregoing), except for those patents or patent applications
listed in Exhibit B.

 

1.10
“NDT Nonexclusive Licensed Patent Rights” means NDT’s rights under: (a) all patents and patent applications
listed in Exhibit B attached hereto, (b) any patents issuing therefrom; and (c) any patents or patent applications claiming a
right of priority thereto (including reissues, reexaminations, renewals, extensions, divisionals, continuations, continued prosecution
applications, continuations-in-part and foreign counterparts of any of the foregoing), except for those patents or patent applications
listed in Exhibit A.

 

    	-2-

    	 

    

 

1.11
“Net Revenue” means all amounts received by CDx and/or its Affiliates from the sale, licensing, or other distribution
(whether commercial or not) to other parties of Sublicensed Products, less Deductible Expenses.

 

1.12
“Person” means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated
organization or government or political subdivision thereof.

 

1.13
“Royalty Term” means the period commencing on the Effective Date and continuing until the expiration, revocation,
invalidation, or unenforceability of any or all intellectual property rights (whether under patent, copyright, or trade secret)
licensed to CDx hereunder, unless earlier terminated pursuant to the terms of this Agreement.

 

1.14
“Territory” means all of the countries and territories in the world.

 

1.15
“Third Party” means any Person other than NDT, CDx or its Affiliates.

 

1.16
“Valid Claim” means: (a) a claim of an issued patent within the NDT Exclusive Licensed Patent Rights or NDT
Nonexclusive Licensed Patent Rights that has not (i) expired or been canceled, (ii) been finally adjudicated to be invalid or
unenforceable by a decision of a court or other appropriate body of competent jurisdiction (and from which no appeal is or can
be taken), (iii) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (iv) been abandoned
in accordance with or as permitted by the terms of this Agreement or by mutual written agreement; or (b) a claim included in a
pending patent application within the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights which claim
is being actively prosecuted in accordance with this Agreement and which has not been (i) canceled, (ii) withdrawn from consideration,
(iii) finally determined to be unallowable by the applicable governmental authority (and from which no appeal is or can be taken),
or (iv) abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement.

 

ARTICLE
2

SUBLICENSES

 

2.1
Grant of Sublicense to CDx. Subject to the terms and conditions of this Agreement, NDT hereby grants to CDx with effect
from the Effective Date the following licenses:

 

(a)an
exclusive, royalty-bearing license under the NDT Exclusive Licensed Patent Rights listed in Exhibit A to make, have made, use,
sell, and offer for sale Sublicensed Products in the Territory in the CDx Field of Use;

 

(b)a
non-exclusive, royalty-bearing license under the NDT Nonexclusive Licensed Patent Rights listed in Exhibit B to make, have made,
use, sell, and offer for sale Sublicensed Products in the Territory in the CDx Field of Use; and

 

    	-3-

    	 

    

  

(c)
a non-exclusive, royalty-bearing license under the Technology to make, have made, use, sell, and offer for sale Sublicensed Products
in the Territory in the CDx Field of Use;

 

These
licenses are personal to and nontransferable by Licensee, except as provided in Section 13.2 (Assignment).

 

2.2
Reservation of Rights; Government Rights. CDx acknowledges that these licenses are subject to: (a) the reservation of the
University’s right to make, have made, import, use, sell and offer for sale Sublicensed Products for noncommercial educational
and research purposes, but not for commercial sale or other commercial distribution to third parties; and (b) any existing right
of the U.S. Government under Title 35, United States Code, Section 200 et seq. and under 37 Code of Federal Regulations, Section
401 et seq., including but not limited to the grant to the U.S. Government of a nonexclusive, nontransferable, irrevocable, paid-up
license to practice or have practiced any invention conceived or first actually reduced to practice in the performance of work
for or on behalf of the U.S. Government throughout the world. In addition, CDx acknowledges that the University reserves the right
to grant the NDT Exclusive Licensed Patent Rights and associated technology to other non-profit institutions for educational and
research purposes. CDx agrees that all Sublicensed Products covered by an NDT Exclusive Licensed Patent Right, and to be sold,
licensed, distributed or used by or on behalf of CDx or its Affiliates in the United States, shall be manufactured substantially
in the United States to the extent (if at all) required by 35 U.S.C. Section 204.

 

2.3
Sublicensing. CDx shall not have the right to grant further sublicenses without express prior written permission of NDT.
Any terms pertaining to further sublicenses shall be the subject of a separate written agreement.

 

2.4
Preferential Purchaser Status.CDx agrees that NDT and University shall be entitled to purchase Sublicensed Products
from CDx for educational, research or other noncommercial purposes on pricing terms that are at least as favorable as any commercial
pricing made available by CDx to any Third Party.

 

2.5
No Other Rights. The parties agree that neither this Agreement, nor any action of the parties related hereto, may be interpreted
as conferring by implication, estoppel, or otherwise, any license or rights under any intellectual property rights of NDT or the
University other than as expressly and specifically set forth in this Agreement, regardless of whether such other intellectual
property rights are dominant or subordinate to the NDT Exclusive Licensed Patent Rights or the NDT Nonexclusive Licensed Patent
Rights. The parties agree that neither this Agreement, nor any action of the parties related hereto, may be interpreted as conferring
by implication, estoppel, or otherwise, any license or rights from CDx or its Affiliates to NDT or the University, including,
but not limited to, all data, testing results and correlation of the data and testing results (“Data”) generated by
CDx regarding any sensor or sensor array, which Data is the sole and exclusive property of CDx, unless ownership is otherwise
designated in a Joint Development Agreement. The Data is provided to NDT for sensor development solely for CDx and its Affiliates.

 

    	-4-

    	 

    

 

ARTICLE
3

LICENSE
FEE AND ROYALTIES

 

3.1
License Fee. In partial consideration of the rights and licenses granted by NDT hereunder, CDx shall pay to NDT a license
fee of                            
payable within thirty (30) days after the Effective Date.

 

3.2
Timing and Computation. All royalties hereunder shall be computed on a quarterly basis for the quarters ending March 31st,
June 30th, September 30th, and December 31st of each calendar year. Royalties for each such quarter
shall be due and payable within thirty (30) days after the end of such quarter.

 

3.3
Valid Claims. For any country in which the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Patent Rights include
a Valid Claim, CDx shall pay NDT royalties as follows:

 

(a)                    %)
of Net Revenues attributable to each Sublicensed Product that is a sensor or sensor array not purchased from NDT by CDx or its
Affiliates and that is made, sold, licensed, distributed or used, by or on behalf of CDx or its Affiliates in such country;

 

(b)                    %)
of Net Revenues attributable to each Sublicensed Product that is not a sensor or sensor array and that is made, sold, licensed,
distributed or used, by or on behalf of CDx or its Affiliates in such country;

 

(c)                    %)
of Net Revenues attributable to each Accessory of a Sublicensed Product that is not a sensor or sensor array and that is made,
sold, licensed, distributed or used, by or on behalf of CDx or its Affiliates in such country;

 

3.4
Technology. For any country in which the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Patent Rights do not
include a Valid Claim, CDx shall pay NDT a royalty of                     %)
of Net Revenues for each Sublicensed Product made, sold, licensed, distributed or used by or on behalf of CDx or its Affiliates
for a period of five (5) years from a first commercial sale.

 

3.5
Minimum Annual Royalties. During the Term and in further consideration of the rights and licenses granted by NDT hereunder,
CDx shall pay to NDT minimum annual royalties in the amount of                         ),
which amount shall be payable in equal quarterly installments and which shall be creditable against the royalties payable to NDT
pursuant to Sections 3.3 and 3.4. This minimum annual royalty shall be increased to                            )
at the beginning of the calendar quarter immediately after the earliest to occur of (a) the second anniversary of the Effective
Date or (b) the first commercial sale of a Sublicensed Product. For any partial calendar year, such minimum annual royalty shall
be determined on a pro rata basis.

 

    	-5-

    	 

    

  

3.6
Bundled Products and Services. In the event that Sublicensed Products are sold, licensed, distributed or used in combination
with one or more other products or services which are not Sublicensed Products, the Net Revenues for such combination products
will be calculated on a country-by-country basis by multiplying actual net sales (calculated on the basis as if they were Net
Revenues) of such combination products by the fraction A/(A+B) where A is the average invoice price, during the relevant quarterly
period, of the Sublicensed Product when sold or licensed separately by CDx or an Affiliate, and B is the average invoice price
during such period of any other product(s) or services in the combination when sold or licensed separately by CDx or an Affiliate.
If the products or services in the combination that are not Sublicensed Products have not been sold or licensed separately by
CDx or an Affiliate in the relevant quarterly period, Net Revenues shall be calculated by multiplying actual net sales (calculated
on a basis as if they were Net Revenues) of such combination products by the fraction A/C where A is the average invoice price,
during the last quarterly period, of the Sublicensed Product when sold or licensed separately and C is the average invoice price
of the combination product during such period. If the Sublicensed Product has not been sold or licensed separately by CDx or an
Affiliate in the last quarterly period, regardless of whether the combination product without the Sublicensed Product is sold
or licensed separately, Net Revenues shall be calculated as in the immediately preceding sentence except that A shall be the total
manufacturing cost of Sublicensed Product and C shall be the total manufacturing cost of the combination.

 

3.7
Third Party Offset. If CDx or an Affiliate is required to make any payment (including, but not limited to, royalties or
other license fees) to one or more third parties to obtain a patent license in the absence of which it could not legally make,
import, use, sell, or offer for sale Sublicensed Products in any country, and CDx provides NDT with reasonably satisfactory evidence
of such third-party payments, such third-party payments shall be fully creditable against royalties owed to NDT hereunder, provided
that in no one year shall the aggregate of all such expenses be credited against more than                    %)
of royalty payments to NDT. Any greater amount of such expenses may be carried over and credited against royalties owed in future
years, subject in every case to the 25% annual cap for that year.

 

3.8
Currency Conversion. For the purpose of determining royalties payable under this Agreement, any Net Revenues denominated
in currencies other than U.S. dollars shall be converted into U.S. dollars according to the noon buying rate of the Federal Reserve
Bank of New York on the last business day of the quarterly period for which such royalties are calculated.

 

3.9
Convenience of the Parties. NDT and CDx acknowledge that each of the royalties set forth in this Section 3 represents an
integrated royalty established for the convenience of the parties in order to avoid the technical, legal and accounting complexities
of analyzing and apportioning the relative contributions of the various forms of patent, copyright, and/or trade secret rights
licensed to, and the various forms of technical assistance (if any) provided to, CDx in connection with the Sublicensed Products.

 

3.10
CDx shall keep complete and accurate production and accounting records relating to commercialization of Sublicensed Products.
NDT shall be entitled to have an independent CPA periodically audit such records upon thirty (30) days’ notice, during CDx’s
normal business hours, to determine CDx’s compliance with the provisions of this Article 3. CDx shall reimburse NDT one
hundred percent (100%) of any unpaid royalties resulting from any noncompliance discovered as a result of any such audit; and
CDx shall also pay NDT an additional                    %)
of the entire amount of any underpayment exceeding ten percent (10%) of the corresponding amount previously paid. Such audits
shall be at NDT’s expense, and shall occur no more than once annually, except that in the case of any underpayment exceeding
ten percent (10%) of the amount actually paid: (a) CDx shall reimburse NDT for the cost of such audit; and (b) NDT shall be entitled
to conduct additional quarterly audits, at CDx’s expense, until any such audit demonstrates that CDx is in compliance with
its obligations under this Agreement.

 

    	-6-

    	 

    

 

3.11
Royalty Payments and Reports. Royalties due under this Article 3 shall be payable on a country-by-country and Sublicensed
Product-by-Sublicensed Product basis until the expiration of the last-to-expire issued Valid Claim covering such Sublicensed Product
in such country, or if no such patent has previously issued in a country, until the fifth anniversary of the first commercial
sale of Sublicensed Product in any country. For so long as royalties are payable under this Agreement, CDx shall provide a royalty
report in writing to NDT on or before April 30th, July 31st, October 31st, and January 31st
of each year. The report shall include, for all Sublicensed Products that are sold or otherwise distributed by CDx and its
Affiliates, on a country-by-country basis:

 

(a)a
description of all Sublicensed Products;

 

(b)number
of Sublicensed Products sold;

 

(c)total
revenues from each of the Sublicensed Products received by CDx and its Affiliates;

 

(d)Deductible
Expenses for each of the Sublicensed Products;

 

(e)Net
Revenues from Sublicensed Product(s);

 

(f)royalties
on Net Revenues due to NDT; and

 

(h)
foreign currency conversion rate and calculations (if applicable) and total royalties due.

 

Each such
report shall also set forth an explanation of the calculation of the royalties payable hereunder and be accompanied by payment
of the royalties shown by said report to be due NDT.

 

3.12
Single Royalty. No more than one royalty payment shall be due with respect to a sale of a particular Sublicensed Product.
No multiple royalties shall be payable because any Sublicensed Product, or its manufacture, sale or use is covered by more than
one Valid Claim in a given country.

 

3.13
Milestone Payments. CDx shall make the following one-time payments to NDT when cumulative Net Revenue from Sublicensed
Products in the Territory reach certain thresholds as set forth in the table below for the first time. Each milestone payment
by CDx to NDT under this Section 3.13 shall be payable only once, and in no event shall the aggregate amount to be paid by CDx
under this Section 3.13 exceed                         ).

 

    	-7-

    	 

    

 

	Threshold for cumulative Net Revenue in the Territory	 	Milestone Payment
	                   	 	              
	                   	 	              
	                   	 	              

  

ARTICLE
4

DILIGENCE

 

4.1
Diligence. CDx agrees to use reasonable efforts to commercially introduce Sublicensed Product(s) as soon as practicable.
CDx shall be deemed to have satisfied its obligations under this Section 4.1 if CDx invests at least                    )
per year in research and development activities towards the commercialization of Sublicensed Product(s) in the Territory for the
CDx Field of Use until annual gross sales of Sublicensed Products equals or exceeds                    ).
For the purpose of this Section 4.1, research and development investments include amounts expended by CDx itself, directly or
through its Affiliates for both internal research development and research and development activities performed on CDx’s
behalf by third parties.

 

4.2
Reporting. On each yearly anniversary of the Effective Date and upon NDT’s request, CDx shall issue to NDT a detailed
written report on its progress in introducing commercial Sublicensed Product(s). Such report shall be considered confidential
information of CDx subject to Article 7.

 

4.3
Failure to Commercialize. If CDx is not fulfilling its obligations under Section 4.1, and NDT so notifies CDx in writing,
NDT and CDx shall negotiate in good faith any additional efforts to be taken by CDx. If the parties do not reach agreement within
thirty (30) days of NDT’s written notice, NDT may terminate this Agreement pursuant to Article 10.

 

ARTICLE
5

PROSECUTION
AND ENFORCEMENT

 

5.1
Maintenance of Core Patent Rights. During the term of this Agreement, NDT shall take all commercially reasonable efforts
to maintain in force the NDT Core Patent Rights. Renewal fees due for the maintenance of the NDT Core Patent Rights and the fees
required to prosecute pending Core Patent Rights will be paid by either NDT or a Third Party. In the event that any payment or
fee is due for the continued maintenance or prosecution of the NDT Core Patent Rights and neither NDT nor another party has paid
those fees, NDT will notify CDx immediately and within 30 days for CDx to act to protect those patent rights at CDx’s sole
option. This section 5.1 does not limit any of the other rights or obligation of either party under this Agreement.

 

5.2
Maintenance of Non-Core Patent Rights. Notwithstanding its obligations under section 5.1, NDT will have no obligation to
maintain or prosecute patent rights that are not Core Patent Rights. If NDT declines to file, prosecute or maintain any patent
rights that are not Core Patent Rights, then NDT will notify CDx and CDx may elect to assume responsibility for such filing, prosecution
or maintenance at its expense in NDT’s name. NDT agrees to fully cooperate with CDx in filing, prosecuting, and maintaining
any such patent applications and patents, and NDT agrees to execute any documents as shall be necessary for such purpose.

 

    	-8-

    	 

    

  

ARTICLE
6

LITIGATION

 

6.1
Enforcement. Both NDT and CDx agree to promptly notify the other in writing should either party become aware of possible
infringement by a Third Party of the NDT Exclusive Licensed Patent Rights in any part of the CDx Field of Use. If CDx has supplied
NDT with evidence of infringement of the NDT Exclusive Licensed Patent Rights, CDx may by notice request NDT to take steps to
enforce the NDT Exclusive Licensed Patent Rights. If NDT does not, within sixty (60) days of the receipt of such notice, initiate
an action against the alleged infringer in the CDx Field of Use, CDx may upon notice to NDT initiate such an action at CDx’s
expense, either in CDx name or in NDT’s name if so required by law. CDx shall be entitled to control any such action initiated
by it.

 

6.2
Other Defensive Litigation. If a declaratory judgment action alleging invalidity, unenforceability or non-infringement
of any of the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights in the CDx Field of Use is brought
against CDx or NDT or the University, CDx may elect to control the defense of such action, and if CDx so elects it shall bear
all the costs of the action. If mutually agreed between the parties, CDx may also undertake the defense of any interference, opposition,
inter partes review, post-grant review or similar procedure with respect to the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive
Licensed Patent Rights in the CDx Field of Use, providing that CDx bears all the costs thereof.

 

6.3
Cooperation. In the event either party takes control of a legal action or defense pursuant to this Sections 6.1 or 6.2,
(thus becoming the “Controlling Party”) the other party shall fully cooperate with and supply all assistance reasonably
requested by the Controlling Party instituting or carrying on such action or defense, including by: (a) using commercially reasonable
efforts to have its employees consult and testify when requested; (b) making available relevant records, papers, information,
samples, specimens, and the like; and (c) joining any such action in which it is an indispensable party. The Controlling Party
shall bear the reasonable expenses (including salary and travel costs) incurred by the other party in providing such assistance
and cooperation. Each party shall keep the other party reasonably informed of the progress of the action or defense, and the other
party shall be entitled to participate in such action or defense at its own expense and using counsel of its choice. As a condition
of controlling any action or defense involving the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights
pursuant to Sections 6.1 or 6.2, CDx shall use its best efforts to preserve the validity and enforceability thereof.

 

6.4
Settlement. If CDx controls any action or defense under Section 6.1 or 6.2, then CDx shall have the right to settle any
claims thereunder, but only upon terms and conditions that are reasonably acceptable to NDT. Should CDx elect to abandon such
an action or defense other than pursuant to a settlement with the alleged infringer that is reasonably acceptable to NDT, CDx
shall give timely advance notice to NDT who, if it so desires, may continue the action or defense.

 

    	-9-

    	 

    

  

6.5
Recoveries. Any amounts paid to CDx by third parties as the result of an action or defense pursuant to Sections 6.1 or
6.2 (including in satisfaction of a judgment or pursuant to a settlement) shall first be applied to reimbursement of the unreimbursed
expenses (including attorneys’ fees and expert fees) incurred by each party. Any remainder shall be divided between the
parties as follows:

 

(a)To
the extent the amount recovered reflects CDx’s lost profits or royalties, CDx shall retain the remainder, less the amount
of any royalties that would have been due NDT under Section 3 on account of such lost profits or royalties, provided that (i)
CDx shall in any event retain at least                    %)
of the remainder; and (ii) NDT shall receive an amount equal to the royalties it would have received if such sales had been made
by CDx, provided such an amount shall in no event exceed                    %)
of the remainder; and

 

(b)To
the extent the amount recovered does not reflect CDx’s lost profits or royalties,                    %)
shall be paid to the party controlling the action at the time of recovery, and                    %)
to the other party.

 

6.6
Infringement Defense. If CDx, its Affiliate or distributor or other customer is sued by a Third Party charging infringement
of patent rights that cover a Sublicensed Product, CDx will promptly notify NDT. CDx will be responsible for the expenses of,
and will be entitled to control the defense or settlement of, any such action(s).

 

6.7
Marking. CDx agrees to mark the Sublicensed Products with the numbers of applicable issued patents within the NDT Exclusive
Licensed Patent Rights, unless such marking is commercially infeasible in accordance with normal commercial practices in the CDx
Field of Use, in which case the parties shall cooperate to devise a commercially reasonable alternative to such marking.

 

6.8
Expiration or Abandonment. In a case where one or more patents or particular claims thereof within the NDT Exclusive Licensed
Patent Rights or NDT Nonexclusive Licensed Patent Rights expire, or are abandoned, or are declared invalid or unenforceable by
a court of last resort or by a lower court from whose decree no appeal is taken, or certiorari is not granted within the period
allowed therefore, then the effect thereof hereunder shall be:

 

(a)that
such patents or particular claims shall, as of the date of expiration or abandonment or final decision as the case may be, cease
to be included within the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights for the purpose of this
Agreement; and

 

(b)that
such construction so placed upon the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights by the court
shall be followed from and after the date of entry of the decision, and royalties shall thereafter be payable by CDx only in accordance
with such construction.

 

In
the event that CDx challenges the validity of NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights,
CDx may not cease paying royalties as of the date validity of the claims in issue are challenged, but rather may cease paying
royalties as to those claims only after a final adjudication of invalidity of those claims.

 

    	-10-

    	 

    

  

6.9
Adjustment. In the event that any of the contingencies provided for in Paragraph 6.8 occurs, NDT agrees to renegotiate
in good faith with CDx a reasonable royalty rate under the remaining NDT Exclusive Licensed Patent Rights or NDT Nonexclusive
Licensed Patent Rights which are unexpired and in effect and under which CDx desires to retain a license.

 

6.10
Sublicensee Challenge. If CDx or any of its Affiliates brings an action or proceeding, or assists any Third Party in bringing
an action or proceeding, seeking a declaration or ruling that any claim in any of the NDT Exclusive Licensed Patent Rights or
NDT Nonexclusive Licensed Patent Rights is invalid or unenforceable:

 

(a)during
the pendency of such action or proceeding, the royalty rate will be increased to double the royalty rate set forth in Section
3.3;

 

(b)should
the outcome of such action or proceeding determine that any claim of a Sublicensed Patent challenged by CDx is valid, enforceable,
and/or infringed by a Sublicensed Product, the royalty rate will be increased to triple the royalty rate set forth in Section
3.3 and CDx shall pay NDT’s attorneys' fees, expert witness fees, court costs, third-party costs, and other litigation expenses;

 

(c)CDx
shall have no right to recoup any royalties paid before such action or proceeding or during the period in which such action or
proceeding is pending (including on appeal);

 

(d)CDx
shall not pay royalties into any escrow or other similar account, but rather shall continue to pay royalties directly to NDT;
and

 

(e)NDT
shall have full control and authority to defend the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights
in the action or proceeding.

 

CDx
shall provide written notice to NDT at least ninety (90) days before CDx or any of its Affiliates initiates any action or proceeding
seeking a declaration or ruling that any claim of any NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent
Rights is invalid or unenforceable or that any product would not infringe (but for this Agreement) any claim in the NDT Exclusive
Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights. Licensee will include with such written notice an identification
of all prior art it believes is material.

 

Any
dispute regarding the validity or enforceability of any of the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed
Patent Rights, or whether any product would infringe (but for this Agreement) any claim in the NDT Exclusive Licensed Patent Rights
or NDT Nonexclusive Licensed Patent Rights, shall be litigated exclusive in the U.S. District Court for the Central District of
California situated in the County of Los Angeles, and each Party hereby agrees to submit to the exclusive jurisdiction of such
court, and waives any objection to venue, for such purposes.

 

    	-11-

    	 

    

 

ARTICLE
7

CONFIDENTIALITY

 

7.1
Confidential Information. During the term of this Agreement, except as provided herein, each Party shall maintain in confidence,
and shall not use for any purpose or disclose to any Third Party, information that is disclosed by the other Party in writing
and marked “Confidential” or that is disclosed orally and confirmed in writing as confidential within forty-five (45)
days following such disclosure (collectively, “Confidential Information”). Confidential Information shall not
include any information that is: (i) already known to the receiving Party at the time of disclosure hereunder, or (ii) now or
hereafter becomes publicly known other than through acts or omissions of the receiving Party, or (iii) is disclosed to the receiving
Party by a Third Party under no obligation of confidentiality to the disclosing Party or (iv) independently developed by the receiving
Party without use of or reference to the Confidential Information of the disclosing Party.

 

7.2
Permitted Usage. Each Party may use and disclose Confidential Information of the other Party as follows: (i) under appropriate
confidentiality provisions substantially equivalent to those in this Agreement, in connection with the performance of its obligations
or exercise of rights granted to such Party in this Agreement (ii) in connection with the filing for, prosecution, maintenance
and enforcement of the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Licensed Patent Rights in accordance with this
Agreement, complying with the terms of agreements with third parties, prosecuting or defending litigation, complying with applicable
governmental regulations, filing for, obtaining and maintaining regulatory approvals, or otherwise required by applicable Law,
provided, however, that if a Party is required by Law to make any such disclosure of the other Party’s Confidential Information
it will, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure
requirement and, except to the extent inappropriate in the case of patent applications, will use its reasonable efforts to secure
confidential treatment of such Confidential Information required to be disclosed; (iii) in communication with existing and potential
investors, consultants, advisors (including financial advisors, lawyers and accountants) and others on a need to know basis, in
each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or (iv) to the extent
mutually agreed to by the Parties. Except as set forth in this Section 7.2, neither party may use or disclose Confidential Information
of the other Party. Each Party shall take at least those measures that it employs to protect its own confidential information
of a similar nature to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information of the
other Party, but in no event less than a reasonable degree of care.

 

7.3
Confidential Terms. Each of the Parties agrees not to disclose to any Third Party the terms and conditions of this Agreement
without the prior approval of the other Party, (i) except to advisors (including consultants, financial advisors, attorneys and
accountants) and potential and existing investors, in each case under circumstances that reasonably protect the confidentiality
thereof, or (ii) to the extent necessary to comply with the terms of agreements with third parties, or (iii) except to the extent
necessary to comply with applicable Law, including securities laws.

 

    	-12-

    	 

    

 

ARTICLE
8

INDEMNIFICATION

 

8.1
Indemnification by NDT. NDT hereby agrees to defend, hold harmless and indemnify CDx and its Affiliates, and its and their
agents, directors, officers and employees from and against any liability or expense (including reasonable legal expenses and attorneys’
fees) resulting from suits, claims, actions and demands, in each case brought by a Third Party arising out of a material breach
of any of NDT’s representations and warranties under Article 9, provided that (a) NDT is notified promptly of any third-party
claim; (b) NDT has the sole right to control and defend or settle any litigation within the scope of this indemnity; and (c) all
indemnified parties cooperate to the extent necessary in defense of any third-party claims. The foregoing shall be the sole and
exclusive remedy of CDx for breach of Article 9.

 

8.2
Indemnification by CDx. CDx hereby agrees to defend, hold harmless and indemnify NDT and its Affiliates, and its and their
agents, directors, officers and employees from and against any liability or expense (including reasonable legal expenses and attorneys'
fees) resulting from suits, claims, actions and demands, in each case brought by a Third Party (1) arising out of a material breach
of any of CDx's representations and warranties under Article 9, or (2) relating to the manufacture, sale, licensing, distribution
or use of Sublicensed Products by or on behalf of CDx or its Affiliates, except to the extent involving or relating to a material
breach by NDT of its representations and warranties. CDx hereby further agrees to indemnify, defend and hold harmless the University,
its trustees, agents and employees from and against any and all losses, damages, costs and expenses (including reasonable attorneys'
fees) arising out of Third Party claims brought against the University relating to the manufacture, sale, licensing, distribution
or use of Sublicensed Products by or on behalf of CDx or its Affiliates.

 

8.3
Certain Damages. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES
ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

 

ARTICLE
9

REPRESENTATIONS
AND WARRANTIES

 

9.1
General Representations and Warranties. Each Party represents and warrants to the other that: (i) it is duly organized
and validly existing under the Laws of the jurisdiction of its incorporation, and has full corporate power and authority to enter
into this Agreement and to carry out the provisions hereof; (ii) it is qualified to do business and is in good standing in each
jurisdiction in which it conducts business; (iii) it is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite
corporate action; (iv) this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution,
delivery and performance of this Agreement and it does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, nor violate any material applicable Law; and (v) it is not aware of any action,
suit or inquiry or investigation instituted by any entity which questions or threatens the validity of this Agreement.

 

    	-13-

    	 

    

  

9.2
NDT Representations and Warranties. NDT represents and warrants to CDx that (i) it will maintain in full force and effect
a valid license agreement to the NDT Core Patent Rights in the CDx Field of Use, (ii) it has a valid and enforceable written license
to all NDT Exclusive Licensed Patent Rights and NDT Nonexclusive Patent Rights in the CDx Field of Use; (iii) it has the right
and authority to enter into this Agreement and grant CDx the licenses and rights granted under this Agreement; (iv) it has disclosed
to CDx all material information known to NDT as of the Effective Date relating to the prospects for issuance of patents from the
patent applications constituting the NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Patent Rights and the potential
validity and enforceability of such patents; v) all Technology delivered prior to the date of Execution of this Agreement has
been, and all Technology delivered hereafter will be, materially accurate and complete; vi) it has not previously granted and
will not grant any right, license or interest in NDT Exclusive Licensed Patent Rights or NDT Nonexclusive Patent Rights in the
CDx Field of Use, or any portion thereof, inconsistent with the rights and licenses granted to CDx herein; (vii) to its knowledge,
there are no threatened or pending claims of third parties that would call into question the right of NDT to grant to CDx the
rights granted hereunder.

 

9.3
CDx Representations and Warranties. CDx represents and warrants that it will manufacture, sell or otherwise distribute
Licensed Products in the CDx Field of Use pursuant to the terms of this Agreement.

 

9.4
Disclaimers.

 

(a)As
Between the Parties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS, WARRANTIES
OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER HEREOF OR ANY REPRESENTATIONS OR GIVES
ANY WARRANTIES THAT ANY LICENSED PRODUCTS WILL SUCCESSFULLY BE DEVELOPED USING THE RIGHTS UNDER THIS AGREEMENT, OR THAT ANY SUCH
LICENSED PRODUCTS WILL HAVE COMMERCIAL UTILITY OR REGULATORY ACCEPTABILITY, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL
IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES AND CONDITIONS OF
THE VALIDITY OF THE LICENSED PATENTS OR NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

 

(b)By
NDT. NDT HEREBY DISCLAIMS, ANY EXPRESS OR IMPLIED REPRESENTATION, WARRANTY, COVENANT, OR OTHER OBLIGATION THAT ANY PRACTICE
BY OR ON BEHALF OF CDX OF ANY INTELLECTUAL PROPERY SUB-LICENSED HEREUNDER IS OR WILL BE FREE FROM INFRINGEMENT OF RIGHTS OF THIRD
PARTIES.

 

(c)Acknowledgment
of University Disclaimer. CDx acknowledges and accepts that, pursuant to the University License Agreement, University has
disclaimed any express or implied representation, warranty, covenant or other obligation: (a) that any practice by or on behalf
of NDT of any NDT Exclusive Licensed Patent Rights and NDT Nonexclusive Patent Rights is or will be free from infringement of
third parties; and (b) as to warranties of merchantability, fitness for a particular purpose, or non-infringement of Third Party
rights, with respect to NDT Exclusive Licensed Patent Rights and NDT Nonexclusive Patent Rights.

 

    	-14-

    	 

    

 

ARTICLE
10

TERM
AND TERMINATION

 

10.1
Term. Unless terminated earlier pursuant to this Article 10, the term of this Agreement shall commence on the Effective
Date and continue in full force for the duration of the Royalty Term (the “Term”) upon which the Agreement
expires. Upon expiration of the Agreement, the licenses and rights granted to CDx shall be fully paid and royalty-free.

 

10.2
Termination

 

(a)By
Either Party for Breach. If either Party is in material breach of this Agreement, including the non-payment of Royalties,
the other Party must provide notice of such breach in writing. If the Party in breach does not cure that breach within sixty 60
days, the other party may terminate this Agreement.

 

(b)By
Either Party for Insolvency. This Agreement shall terminate, without notice, if at any time either Party (A) shall become
insolvent, (B) shall cease to carry on its business, is dissolved or shall go into liquidation, whether compulsory or voluntary
(other than a voluntary liquidation for the purpose of reconstruction or amalgamation), (C) shall have an Insolvency Officer appointed
over the whole or any part of its assets, (D) institutes or has instituted against it by a Third Party a proceeding seeking a
judgment of insolvency or bankruptcy or any other relief under any bankruptcy or insolvency law or other similar law affecting
creditor’s rights, or a petition is presented for its winding-up or liquidation, and, in the case of any such proceeding
or petition instituted or presented against it, such proceeding or petition results in a judgment of insolvency or bankruptcy
or the entry of an order for relief or the making of an order for its winding-up or liquidation or is not dismissed, discharged,
stayed or restrained in each case within thirty (30) days of the institution or presentation thereon, or (E) has a secured party
take possession of all or substantially all of its assets or has a distress, execution, attachment, sequestration or other legal
process levied, enforced or sued on or against all or substantially all its assets and such secured party maintains possession,
or any such process is not dismissed, discharged, stayed or restrained, in each case within thirty (30) days thereafter, then,
and in any of the foregoing events (each an “Insolvency Event”). Either Party may terminate this Agreement upon the
insolvency of the other Party. Each Party agrees to inform the other Party of its intention to file a voluntary petition of bankruptcy,
at least thirty (30) days prior to the filing of such a petition. Either Party’s filing without conforming to this requirement
shall be deemed a material, pre-petition incurable breath of this Agreement which will cause this Agreement to terminate without
notice upon such filing.

 

(c)By
NDT for Non-Productivity. NDT may terminate this Agreement upon 60-days written notice if CDX (a) fails to sell to third-party
customers at least one thousand (1,000) units of Sublicense Product in any calendar year, or (b) does not fulfill its due diligence
obligations under Section 4.3. The right to terminate shall not apply if failure to sell Sublicensed Products are substantially
the result of any failure or delay by NDT.

 

    	-15-

    	 

    

 

(d)By
CDx for any Reason. Any provision herein notwithstanding, CDx shall have the right to terminate this Agreement by giving NDT
ninety (90) days’ prior written notice referencing this Section 10.2(a).

 

(e)Effect
of Termination of University License Agreement. In the event that CDx terminates this Agreement for a material breach of this
Agreement by NDT under Section 10.2(a) or as a result of an Insolvency Event by NDT under Section 10.2(b), any sublicenses granted
to NDT Exclusive Licensed Patent Rights and NDT Nonexclusive Patent Rights by NDT pursuant to this Agreement shall survive termination
of this Agreement under the University License Agreement, provided that the following conditions are met as of the date of such
termination:

 

(1)CDx
agrees to render to University all royalties or other consideration that CDx would have owed to NDT under this Agreement;

 

(2)CDx
agrees that University is a Third Party beneficiary under this Agreement; and

 

(3)CDx
agrees to hold NDT responsible for all obligations to CDx (other than those requiring NDT to hold a license under the NDT Exclusive
Licensed Patent Rights and NDT Nonexclusive Patent Rights) unless University agrees to assume such obligations.

 

10.3
Effect of Termination/Expiration.

 

(a)Retain
Amounts Paid. In the event of termination of this Agreement, NDT shall have the right to retain all amounts paid hereunder
prior to the effective date of such termination.

 

(b)Reversion
of Rights. As of the effective date of a termination of this Agreement, the rights of CDx in the NDT Exclusive Licensed Patent
Rights and NDT Nonexclusive Patent Rights and Technology shall revert to NDT, except as provided in Section 10.2(e) and 10.3(c).

 

(c)Post-Termination
Sales of Sublicensed Product. CDx may, for a period of no longer than six (6) months after the effective date of the termination
of the Agreement, complete and sell any or all Sublicensed Products that were in the process of manufacture or in inventory on
the effective date of the termination; provided, however, that it shall remain obligated to pay any and all applicable Royalties
thereon and other amounts related thereto as provided in this Agreement, and the terms and conditions of this Agreement applicable
thereto shall remain in full force and effect during such six (6)-month period.

 

(d)No
Release. Termination or expiration of this Agreement shall not release either Party hereto from any liability which at the
time of such termination or expiration has already accrued to the other Party.

 

(e)Survival.
Articles 1, 7 (for the period set forth therein), 8, 11, 12 and 13 and Sections 3.10 (for the period set forth therein), 9.4,
and 10.3 shall survive the expiration and any termination of this Agreement. Except as otherwise provided in this Article 10 all
other provisions of this Agreement shall terminate upon the expiration or termination of this Agreement.

 

    	-16-

    	 

    

 

ARTICLE
11

DISPUTE
RESOLUTION

 

11.1
Disputes. In the event of any dispute between the Parties arising out of or in connection with this Agreement, either Party
may, by written notice to the other, have such dispute referred to the Chief Executive Officers of NDT and CDx for attempted resolution
by good faith negotiations within thirty (30) days after such notice is received, and in such event, each Party shall cause its
representative to meet and be available to attempt to resolve such issue. Notwithstanding the foregoing, neither Party shall be
obligated to negotiate for more than thirty (30) days. If the Parties should resolve such dispute or claim, a memorandum setting
forth their agreement will be prepared and signed by both Parties if requested by either Party.

 

11.2
Arbitration. In the event that the Parties are unable to resolve any such matter pursuant to Section 11.1, then either
Party may initiate arbitration pursuant to this Section 11.2. Any arbitration under this Section 11.2 shall be conducted by Judicial
Arbitration and Mediation Services (“JAMS”) in San Diego in accordance with the applicable JAMS rules by a
single arbitrator, unless an alternative arbitrator service and rules are agreed to by the parties. In such arbitration, the arbitrator
shall select an independent expert with significant experience relating to the subject matter of such dispute to advise the arbitrator
with respect to the subject matter of the dispute. If the Parties are unable to agree on an arbitrator, the arbitrator shall be
selected by the chief executive of the San Francisco office of JAMS. The costs of such arbitration shall be shared equally by
the Parties, and each Party shall bear its own expenses in connection with the arbitration. The Parties shall use good faith efforts
to complete arbitration under this Section 11.2 within sixty (60) days following the initiation of such arbitration. The arbitrator
shall establish reasonable additional procedures to facilitate and complete such arbitration within such sixty (60) day period.
Nothing in this Agreement shall limit the right of either Party to seek to obtain in any court of competent jurisdiction any equitable
or interim relief or provisional remedy, including injunctive relief.

 

ARTICLE
12

PRODUCT
LIABILITY

 

12.1
Indemnification. CDx agrees that NDT and its Affiliates and University (including its trustees, officers, faculty and employees)
shall have no liability to CDx, its Affiliates, their customers or any Third Party, for any claims, demands, losses, costs, or
other damages which may result from personal injury, death, or property damage related to the Sublicensed Products (“Product
Liability Claims”). CDx agrees to defend, indemnify, and hold harmless NDT and its Affiliates and the University, its trustees,
officers, faculty and employees from any such Product Liability Claims, provided that: (a) CDx is notified promptly of any Product
Liability Claims; (b) CDx has the sole right to control and defend or settle any litigation within the scope of this indemnity;
and (c) all indemnified parties cooperate to the extent necessary in the defense of any Claims.

 

    	-17-

    	 

    

 

12.2
Insurance. Prior to such time as CDx begins to manufacture, sell, distribute or use Sublicensed Products, CDx shall at
its sole expense, procure and maintain policies of comprehensive general liability insurance in amounts not less than one million
dollars ($1,000,000) per incident and three million dollars ($3,000,000) in annual aggregate, and naming those indemnified under
Section 12.1 as additional insureds. Such comprehensive general liability insurance shall provide: (a) product liability coverage;
and (b) broad form contractual liability coverage for CDx’s indemnification of NDT and the University under Section 12.1.
In the event the aforesaid product liability coverage does not provide for occurrence liability, CDx shall maintain such comprehensive
general liability insurance for a reasonable period of not less than five (5) years after it has ceased commercial distribution
or use of any Sublicensed Product. Licensee shall provide NDT with written evidence of such insurance upon request of NDT.

 

12.3
Loss of Coverage. CDx shall provide NDT with notice at least fifteen (15) days prior to any cancellation, non-renewal or
material change in such insurance, to the extent CDx receives advance notice of such matters from its insurer. If CDx does not
obtain replacement insurance providing comparable coverage within sixty (60) days following the date of such cancellation, non-renewal
or material change, NDT shall have the right to terminate this Agreement effective at the end of such sixty (60) day period without
any additional waiting period; provided that if CDx provides credible written evidence that is has used reasonable efforts, but
is unable, to obtain the required insurance, NDT shall not have the right to terminate this Agreement, and NDT instead shall cooperate
with CDx to either (at NDT’s discretion) grant a limited waiver of CDx’s obligations under this Article or assist
CDx in identifying a carrier to provide such insurance or in developing a program for self-insurance or other alternative measures.

 

ARTICLE
13

GENERAL 

 

13.1
Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State
of California, United States of America, without reference to principles of conflicts of law.

 

13.2
Assignment. This Agreement may not be assigned by either Party, whether by operation of law or otherwise, without the prior
written consent of the other Party. Notwithstanding the foregoing, either Party may, without such consent, assign this Agreement
and its rights, obligations and interests (i) to an Affiliate that is under control of the subject Party, or (ii) in connection
with a merger, acquisition, or sale involving all or substantially all of the subject Party’s business or assets provided
that any assignee under such circumstances shall be fully bound by the terms of this Agreement.

 

13.3
Independent Contractors. The Parties agree that the relationship of NDT and CDx established by this Agreement is that of
independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed
to, establish an employment, agency or any other relationship. Except as may be specifically provided herein, neither Party shall
have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any
expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other
Party for any purpose.

 

    	-18-

    	 

    

 

13.4
Force Majeure. Except for the payment of monies, in the event either Party hereto is prevented from or delayed in the performance
of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, earthquake, power shortage or
failure, failure of the transportation system, or any other cause whatsoever beyond the reasonable control of the Party, the Party
so prevented or delayed shall be excused from the performance of any such obligation during a period that is reasonable in light
of such force majeure event.

 

13.5
Notices. Any notice, request, delivery, approval or consent required or permitted to be given under this Agreement shall
be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified)
or by express courier service (signature required) or five (5) days after it was sent by registered letter, return receipt requested
(or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two (2)
days after such mailing, to the Party to which it is directed at its address or facsimile number shown below or such other address
or facsimile number as such Party will have last given by notice to the other Party.

 

	If
    to NDT:	 	Dr.
    William Royea, President
	 	 	Next
    Dimension Technologies, Inc.
	 	 	1
    West Mountain Street, #11 
	 	 	Pasadena,
    California 91103

 

	If
    to CDx:	 	Daniel
    Yazbeck, CEO
	 	 	CDx
    Inc.
	 	 	4225
    Executive Square Suite 600
	 	 	La
    Jolla, CA, 92037
	 	 	 
	 	 	Attention:
    __________
	 	 	Fax:  
    (858) 434-0705

 

13.6
Compliance with Law. Each Party shall comply with all Laws in connection with its activities pursuant to this Agreement.

 

13.7
No Endorsement. CDx agrees that it shall not make any form of representation or statement which would constitute an express
or implied endorsement by NDT or the University of any Sublicensed Project, and that it shall not authorize others to do so, without
first having obtained written approval from NDT / the University, except as may be required by governmental law, rule or regulation.

 

13.8
No Waiver. A waiver, express or implied, by either NDT or CDx of any right under this Agreement or of any failure to perform
or breach hereof by the other Party hereto shall not constitute or be deemed to be a waiver of any other right hereunder or of
any other failure to perform or breach hereof by such other Party, whether of a similar or dissimilar nature thereto.

 

    	-19-

    	 

    

 

13.9
Severability. If any provision of this Agreement shall be found by a court to be void, invalid or unenforceable, the same
shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability
of the remainder of this Agreement, and the remainder of the Agreement shall remain in full force and effect.

 

13.10
Export Regulations. This Agreement is subject in all respects to the laws and regulations of the United States of America,
including the Export Administration Act of 1979, as amended, and any regulations thereunder. CDx or its sublicensees will not
in any form export, reexport, resell, ship, divert, or cause to be exported, re-exported, resold, shipped, or diverted, directly
or indirectly, any product or technical data or software of the other party, or the direct product of such technical data or software,
to any country for which the United States Government or any agency thereof requires an export license or other governmental approval
without first obtaining such license or approval.

 

13.11
Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect
in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles,
Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement and references to this Agreement include
all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (i) the words “include”
or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation;”
(ii) the word “day” or “year” means a calendar day or year unless otherwise specified; (iii)the word
“notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals
and other written communications contemplated under this Agreement; (iv)the words “hereof,” “herein,”
“hereby” and derivative or similar words refer to this Agreement; (v)the word “or” shall be construed
as the inclusive meaning identified with the phrase “and/or;”(vi) words of any gender include the other gender; and
(vii) words using the singular or plural number also include the plural or singular number, respectively.

 

13.12
Entire Agreement. This Agreement constitutes the entire understanding and agreement between the Parties with respect to
the subject matter hereof and supersedes any and all prior and contemporaneous negotiations, representations, agreements, and
understandings, written or oral, that the Parties may have reached with respect to the subject matter hereof. No agreements altering
or supplementing the terms hereof may be made except by means of a written document signed by the duly authorized representatives
of each of the Parties hereto. For clarity, the Joint Development Agreement shall remain in full force and effect.

 

13.13
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which
together shall constitute one and the same instrument.

 

    	-20-

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of
the Effective Date.

 

	 	 	 
	(NDT)	 	(CDx)
	 	 	 
	By:
    	/s/ William
    Royea	 	By:
    	/s/ Daniel
    Yazbeck
	Name:
    	William
    Royea	 	Name:
    	Daniel
    Yazbeck
	Title:	President	 	Title:	CEO
	Date:
    	5/19/15

	 	Date:
    	5/19/15

 

    	-21-

    	 

    

 

EXHIBIT
A

 

NDT
EXCLUSIVE LICENSED PATENT RIGHTS

 

	Patent #	 	Serial #	 	Title	 	Issue date
	7,359,802	 	10/618,546	 	Methods for Remote Characterizations of an Odor	 	4/15/2008
	7,189,353	 	11/054,055	 	Use of Spatiotemporal Response Behavior in Sensor Arrays to Detect Analytes in Fluids	 	3/13/2007
	7,144,553	 	10/651,917	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	12/5/2006
	6,759,010	 	09/910,243	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	7/6/2004
	6,610,367	 	09/910,242	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	8/26/2003
	6,170,318	 	09/183,724	 	Methods of Use for Sensor Based Fluid Detection Devices	 	1/9/2001
	6,093,308	 	09/258,713	 	Sensors for Detecting Analytes in Fluids	 	7/25/2000
	6,013,229	 	09/095,376	 	Sensor Arrays for Detecting Analytes in Fluids	 	1/11/2000
	6,010,616	 	08/986,500	 	Sensor Arrays for Detecting Analytes in Fluids	 	1/4/2000
	5,959,191	 	09/006,279	 	Sensor Arrays for Detecting Analytes in Fluids	 	9/28/1999
	5,951,846	 	09/006,142	 	Sensor Arrays for Detecting Analytes in Fluids	 	9/14/1999
	5,911,872	 	08/949,730	 	Sensors for Detecting Analytes in Fluids	 	6/15/1999
	5,891,398	 	09/154,604	 	Sensor Arrays for Detecting Analytes in Fluids	 	4/6/1999
	5,788,833	 	08/696,128	 	Sensors for Detecting Analytes in Fluids	 	8/4/1998
	5,698,089	 	08/689,227	 	Sensor Arrays for Detecting Analytes in Fluids	 	12/16/1997
	5,571,401	 	08/410,809	 	Sensor Arrays for Detecting Analytes in Fluids	 	11/5/1996
	DE 0820585	 	696 05 906.1-08	 	Sensor Arrays for Detecting Analytes in Fluids	 	12/29/1999
	3,963,474	 	08-529590/96	 	Sensor Arrays for Detecting Analytes in Fluids	 	6/1/2007
	1,151,272	 	 99960357.4	 	Simultaneous Determination of Equilibrium and Kinetic Properties	 	9/30/2009
	918986	 	97938223.1	 	Sensor Arrays for Detecting Analytes in Fluids	 	10/17/2007
	820585	 	96910563.4	 	Sensor Arrays for Detecting Analytes in Fluids	 	12/29/1999

 

    	 

    	 

    

 

EXHIBIT
B

 

NDT
NONEXCLUSIVE LICENSED PATENT RIGHTS

 

	Patent #	 	Serial #	 	Title	 	Issue date
	8,394,330	 	09/409,644	 	Conductive Organic Sensors, Arrays and Methods of Use	 	3/12/2013
	7,966,132	 	12/082,972	 	Methods for Remote Characterizations of an Odor	 	6/21/2011
	7,955,561	 	11/108,538	 	Colloidal Particles Used in Sensing Arrays	 	6/7/2011
	7,595,023	 	11/490,732	 	Spatiotemporal and Geometric Optimization of Sensor Arrays for Detecting Analytes in Fluids	 	9/29/2009
	7,175,885	 	09/770,089	 	Compositionally Different Polymer-Based Sensor Elements and Method for Preparing Same	 	2/13/2007
	7,122,152	 	09/842,204	 	Spatiotemporal and Geometric Optimization of Sensor Arrays for Detecting Analytes in Fluids	 	10/17/2006
	6,962,675	 	10/214,794	 	Use of Spatiotemporal Response Behavior in Sensor Arrays to Detect Analytes in Fluids	 	11/8/2005
	6,773,926	 	09/963,788	 	Nanoparticle-Based Sensors for Detecting Analytes in Fluids	 	8/10/2004
	6,631,333	 	09/596,758	 	Methods for Remote Characterizations of an Odor	 	10/7/2003
	6,571,603	 	09/318,900	 	Method of Resolving Analytes In a Fluid	 	6/3/2003
	6,455,319	 	09/568,784	 	Use of Spatiotemporal Response Behavior in Sensor Arrays to Detect Analytes in Fluids	 	9/24/2002
	6,387,329	 	09/442,074	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	5/14/2002
	6,350,369	 	09/291,932	 	Method and System for Determining Analyte Activity	 	2/26/2002
	6,290,911	 	09/106,791	 	Compositionally Different Polymer-Based Sensor Elements and Method for Preparing Same	 	9/18/2001
	2,264,839	 	2264839	 	Sensors Arrays for Detecting Analytes in Fluids	 	5/9/2006
	993,605	 	98931709.4	 	Compositionally Different Polymer-Based Sensor Elements and Method for Preparing Same	 	4/19/2000
	334,530	 	334530	 	Sensor Arrays for Detecting Analytes in Fluids	 	7/6/2000
	206,322	 	992497	 	Sensor Arrays for Detecting Analytes in Fluids	 	1/30/2002
	193,532	 	977351	 	Sensor Arrays for Detecting Analytes in Fluids	 	9/27/1999
	n/a	 	99930562.6	 	Polymer/Plasticizer Based Sensor	 	n/a
	n/a	 	99931777.9	 	Colloidal Particles Used In Sensing Arrays	 	n/a
	n/a	 	n/a	 	A Portable Electronic Nose	 	n/a

 

    	-2-

    	 

    

 

EXHIBIT
C

 

CORE
PATENT RIGHTS

 

	Patent #	 	Serial #	 	Title	 	Issue date
	7,359,802	 	10/618,546	 	Methods for Remote Characterizations of an Odor	 	4/15/2008
	7,189,353	 	11/054,055	 	Use of Spatiotemporal Response Behavior in Sensor Arrays to Detect Analytes in Fluids	 	3/13/2007
	7,144,553	 	10/651,917	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	12/5/2006
	6,759,010	 	09/910,243	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	7/6/2004
	6,610,367	 	09/910,242	 	Use of An Array of Polymeric Sensors of Varying Thickness for Detecting Analytes in Fluids	 	8/26/2003
	6,170,318	 	09/183,724	 	Methods of Use for Sensor Based Fluid Detection Devices	 	1/9/2001
	6,093,308	 	09/258,713	 	Sensors for Detecting Analytes in Fluids	 	7/25/2000
	6,013,229	 	09/095,376	 	Sensor Arrays for Detecting Analytes in Fluids	 	1/11/2000
	6,010,616	 	08/986,500	 	Sensor Arrays for Detecting Analytes in Fluids	 	1/4/2000
	5,959,191	 	09/006,279	 	Sensor Arrays for Detecting Analytes in Fluids	 	9/28/1999
	5,951,846	 	09/006,142	 	Sensor Arrays for Detecting Analytes in Fluids	 	9/14/1999
	5,911,872	 	08/949,730	 	Sensors for Detecting Analytes in Fluids	 	6/15/1999
	5,891,398	 	09/154,604	 	Sensor Arrays for Detecting Analytes in Fluids	 	4/6/1999
	5,788,833	 	08/696,128	 	Sensors for Detecting Analytes in Fluids	 	8/4/1998
	5,698,089	 	08/689,227	 	Sensor Arrays for Detecting Analytes in Fluids	 	12/16/1997
	5,571,401	 	08/410,809	 	Sensor Arrays for Detecting Analytes in Fluids	 	11/5/1996
	7,966,132	 	12/082,972	 	Methods for Remote Characterizations of an Odor	 	6/21/2011
	6,571,603	 	09/318,900	 	Method of Resolving Analytes In a Fluid	 	6/3/2003
	6,350,369	 	09/291,932	 	Method and System for Determining Analyte Activity	 	2/26/2002

 

 

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]